News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Women's Health, Inc. (TEVA) Announces for the First Time Results of Pivotal Phase III Study of Quartette™ (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) at the 68th Annual Meeting of American Society for Reproductive Medicine



10/24/2012 9:25:17 AM

FRAZER, Pa.--(BUSINESS WIRE)--Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced the findings from a Phase III pivotal trial of QuartetteTM (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets), an investigational ascending-dose, extended-regimen oral contraceptive for the prevention of pregnancy that is currently under review by the U.S. Food and Drug Administration. These data were presented for the first time as a poster at the 68th Annual Meeting of the American Society of Reproductive Medicine (ASRM).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES